{"componentChunkName":"component---node-modules-gatsby-theme-buzzing-src-gatsby-theme-blog-core-templates-post-query-js","path":"/ja/reddit/r/wallstreetbets/comments/pswpr6/buy_the_dip/","result":{"data":{"site":{"siteMetadata":{"title":"国外股市热门","author":"Buzzing.cc","description":"用中文浏览国外股票社区里的热门讨论","keywords":["buzzing","美股","股票","股市"],"siteUrl":"https://stocks.buzzing.cc","telegram":"@stocks_top","iconUrl":"https://stocks.buzzing.cc/avatar.png","defaultSocialImageUrl":null,"social":[{"name":"Reddit Stocks","url":"https://www.reddit.com/r/stocks","external":true},{"name":"Reddit Investing","url":"https://www.reddit.com/r/investing","external":true},{"name":"Charlie Bilello's twitter","url":"https://twitter.com/charliebilello","external":true},{"name":"Buzzing","url":"https://www.buzzing.cc/","external":true}],"menuLinks":[{"name":"每周精选","url":"/issues","external":null}],"disqus":null,"utterances":null,"localize":[{"title":"Buzzing on Stocks","description":"See popular discussions in foreign stock communities in your native language","keywords":["buzzing","stocks","U.S. stocks"],"locale":"en","social":{"name":null,"url":null,"external":null},"menuLinks":[{"name":"Weekly Selection","url":"/en/issues","external":null}]},{"title":"國外股市熱門","description":"用中文瀏覽國外股票社區裡的熱門討論","keywords":["buzzing","美股","股票","股市"],"locale":"zh-Hant","social":null,"menuLinks":[{"name":"每週精選","url":"/zh-Hant/issues","external":null}]},{"title":"米国株式市場人気の話し合います","description":"人気の米国株式市場の話し合いまを日本語で閲覧","keywords":["buzzing","米国株式市場"],"locale":"ja","social":null,"menuLinks":[]}]}},"blogPost":{"id":"RedditPost-pswpr6","excerpt":"","body":"","slug":"/reddit/r/wallstreetbets/comments/pswpr6/buy_the_dip/","title":"Buy the dip?","tags":["wallstreetbets","reddit"],"date":"September 22, 2021","dateISO":"2021-09-22T08:27:32.000Z","datetime":"2021-09-22 08:27","image":null,"imageAlt":null,"socialImage":null,"__typename":"SocialMediaPost","thirdPartyId":"pswpr6","provider":"Reddit","url":"https://www.reddit.com/r/wallstreetbets/comments/pswpr6/buy_the_dip/","originalUrl":"https://www.reddit.com/r/wallstreetbets/comments/pswpr6/buy_the_dip/","imageRemote":null,"video":null,"channel":"wallstreetbets","channelUrl":"https://www.reddit.com/r/wallstreetbets","author":"ThanosTheBalanced","authorUrl":"https://www.reddit.com/user/ThanosTheBalanced","authorImage":null,"authorImageRemote":null,"authorSlug":"ThanosTheBalanced","score":2605,"views":null,"sharedCount":null,"likeCount":null,"sharedContent":null,"parent":{"localize":[{"title":"ディップを買う？","the_new_excerpt":null,"locale":"ja"},{"title":"买下这块地？","the_new_excerpt":null,"locale":"zh"},{"title":"買下這塊地？","the_new_excerpt":null,"locale":"zh-Hant"}]}},"previous":{"id":"RedditPost-psu3gz","excerpt":"","slug":"/reddit/r/wallstreetbets/comments/psu3gz/ground_hog_day_for_wish_investors/","title":"Ground hog day for $WISH investors","date":"September 22, 2021","__typename":"SocialMediaPost","provider":"Reddit","parent":{"localize":[{"title":"WISHの投資家にとってのグランドホッグデー","the_new_excerpt":null,"locale":"ja"},{"title":"WISH投资者的土豪日","the_new_excerpt":null,"locale":"zh"},{"title":"WISH投資者的土豪日","the_new_excerpt":null,"locale":"zh-Hant"}]}},"next":{"id":"RedditPost-psu0a8","excerpt":"Celltrion is a 32 billion market cap biotech leader developing monoclonal\nanti-bodies for a variety of indications, including COVID-19 (regdanvimab) and a\nwhole mess of other inflammatory diseases such as RA and Crohn's disease.\nThey're going up against Abbvie with a biosimilar for Humira called…","slug":"/reddit/r/stocks/comments/psu0a8/celltrion_and_180_life_sciences/","title":"Celltrion and 180 Life Sciences","__typename":"SocialMediaPost","date":"September 22, 2021","provider":"Reddit","parent":{"localize":[{"title":"セルトリオンと180ライフサイエンス","the_new_excerpt":"Celltrion社は時価総額320億円のバイオテック企業で、様々な分野のモノクローナル抗体を開発しています。\nCOVID-19（レグダンビマブ）をはじめとする様々な適応症のモノクローナル抗体を開発しています。\nCOVID-19（レグダンビマブ）をはじめ、RAやクローン病などの炎症性疾患の治療薬を開発しています。\nアッヴィに対抗して、ヒュミラのバイオシミラーである...","locale":"ja"},{"title":"Celltrion和180生命科学公司","the_new_excerpt":"Celltrion是一家市值320亿美元的生物技术领先企业，为各种适应症开发单克隆\n适应症的单克隆抗体，包括COVID-19 (regdanvimab) 和\n包括COVID-19（regdanvimab）和其他炎症性疾病，如RA和Crohn's疾病的整个混乱。\n他们正在与艾伯维公司对抗，推出名为Humira的生物仿制药。","locale":"zh"},{"title":"Celltrion和180生命科學公司","the_new_excerpt":"Celltrion是一家市值320億美元的生物技術領先企業，爲各種適應症開發單克隆\n適應症的單克隆抗體，包括COVID-19 (regdanvimab) 和\n包括COVID-19（regdanvimab）和其他炎症性疾病，如RA和Crohn's疾病的整個混亂。\n他們正在與艾伯維公司對抗，推出名爲Humira的生物仿製藥。","locale":"zh-Hant"}]}}},"pageContext":{"basePath":"/","pageType":"detail","id":"RedditPost-pswpr6","previousId":"RedditPost-psu3gz","nextId":"RedditPost-psu0a8","maxWidth":1024,"siteMetadata":null,"locale":"ja","hrefLang":"ja-JA","originalPath":"/reddit/r/wallstreetbets/comments/pswpr6/buy_the_dip/","dateFormat":"YYYY-MM-DD"}},"staticQueryHashes":["1239077767","2744905544","3280999885"]}